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study were obtained from the PHARMO Record Linkage
System, including among others linked drug-dispensing and hos-
pital records of approximately three million individuals in
deﬁned areas of The Netherlands. Users of TC during 1992–
2004, without diabetes, with 4 years of follow-up were
selected. Diabetes onset was deﬁned as ﬁrst occurrence (index
date) of an antidiabetic drug dispensing or hospitalization for
diabetes or diabetes-related diagnoses. Each case was matched
by age and sex to 4 controls without diabetes, with similar
follow-up duration. Use of TC and systemic corticosteroids (SC)
and/or inhaled corticosteroids (IC) as co medication were classi-
ﬁed as current (2 years before index date), recent (4–2 years
ago) and past/never (>4 years ago). Multivariate regression
adjusted for co-medication and co-morbidity. RESULTS: Among
192,893 incident TC users, 2,212 developed diabetes and could
be matched to 8,582 controls. Current TC use was associated
with a 1.24 times increased risk of diabetes (95% CI 1.11–1.40).
The Odds Ratio increased to 1.32 with >180 days of TC use and
to 1.44 with a cumulative TC load (combined potency and units)
731–1,460 mg. Cases more often used SC and IC than controls
(23% versus 17% and 18% versus 13% respectively). Among
“Past/never” users of SC and/or IC, risk of diabetes with current
TC use was 1.25 (95% CI 1.09–1.43); among “Current” users of
SC and/or IC, this OR was 1.13 (95%CI 0.88 1.44). CONCLU-
SION: A statistically signiﬁcant effect of TC use on diabetes was
found. Use of TC as skin treatment among patients at increased
risk of diabetes should be considered with some caution.
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OBJECTIVES: To implement a ﬂexible PC program to support
decision makers in evaluating the impact of the use of rosiglita-
zone in eligible diabetic patients on the Italian National Health
System budget. METHODS: Rosiglitazone, an insulin-sensitising
drug, is indicated for subjects with inadequate glycaemic control
both as monotherapy, in those contraindicated to metformin
(especially if overweight) and as combination therapy with met-
formin, sulphonylureas or both. The software developed has a
user-friendly interface and is based on an analytic model, which
pathway may be summarized as follows: a) estimate of the
number of Italian type 2 diabetes patients, grouped according to
current therapeutic classes; b) estimate of the number of patients
with inadequate glycaemic control for each subgroup; c) identi-
ﬁcation of patients eligible to rosiglitazone treatment; d) identi-
ﬁcation of the comparator strategy for each patient sub-group; e)
comparison of costs for each couple of alternative options; and f)
calculation of budget impact. The user can modify most default
data to adapt the analysis to the speciﬁc setting. RESULTS:
Default data based scenario shows that adoption of rosiglitazone
monotherapy induces a mild cost increase. Combination treat-
ments induce signiﬁcant cost savings, related to lower resource
consumption for glycaemic auto-monitoring and hypoglycaemia
management, as compared to standard combination therapies.
The hypothetical scenario in which all eligible Italian patients are
treated with rosiglitazone is estimated to induce net savings for
about 260 millions Euro per year. CONCLUSION: In type 2
diabetes, the maintenance of non-diabetic glycaemic levels has
been shown to decrease the onset of long term complications.
Rosiglitazone represents a further option to postpone insulin
therapy start with a potential cost-saving for the Italian National
Heath System.
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OBJECTIVES: To estimate the economic inefﬁciency of bad
control of Diabetes in terms of direct cost in diabetic patients in
a rural area in Spain (Axarquía) during one-year of follow up.
METHODS: Cohort study of 228 patients (2 rural health centres
sampled in 2005–2006). The perspective analysis was National
Health System. Total cost is composed of four items: insulin and
oral hypoglycaemic agents, glycosylated haemoglobin, dispos-
able and consumable goods (glucose test strips, needles, and
syringes) and primary care visits. The statistical analysis was
made by the SPSS package. For quantitative: mean, DS, IC95%;
for qualitative: proportions. For inferential statistics: Student’s
T-test for quantitative variables and test of Chi-square for the
qualitative ones. Multivariante analysis considered: age, gender,
control grade (ADA, 2006) and interaction gender-control of
DM. The ratio cost-effectiveness and incremental cost of control
compared with non-control of DM was analized with WinBugs
controlled for age and gender. RESULTS: Sixty-seven percent of
females; average age: 69 years. The average of prescribed drugs
for DM control was 1.4 drugs/per patient (1.03% acarbose;
32.99% sulphonylurea; 64.43% biguanide, 13.40% metiglinide
and the 27.32% insuline). The mean of primary care visits
was 14.8/per patient/year. The Diabetes control was 68%
(HbA1c% < 7) with 1.34 drugs per year in controlled patients
versus 1.61 drugs in non-controlled (p < 0.01). The direct health
care cost of diabetic patient was €628/year (CI95%: €576–680).
In patients non haemoglobin glycosilated controlled the cost was
incremented in €193 per patient and the effectiveness decal in
32%. CONCLUSION: This economic study demonstrates the
real possibility to improve the efﬁciency of our interventions. If
we transferred the data found to our area of reference (Málaga)
the saving in costs would be superior to €3 million. Health
providers and policymakers should use this information in
making clinical and policy decisions in order to use resources
efﬁciently.
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OBJECTIVES: To evaluate 2-year real world outcomes of glyce-
mic control in patients with T2DM initiating insulin glargine vs.
NPH insulin. METHODS: Patients with T2DM (March 2001–
March 2005) who failed oral antidiabetic agents, initiated
glargine (n = 2105) or NPH (n = 734), with continuous plan
enrollment for >18 months (6 months (baseline) prior to and 12
months after insulin initiation) and with available laboratory
HbA1C values, were evaluated using a US managed care claims
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database. Baseline demographics, HbA1C, co-morbidities, health
care utilization, pharmacy copayment, and concomitant fol-
lowup antidiabetic medications were controlled. Costs were
evaluated using actual paid claims by health insurance, adjusting
for inﬂation to the most current year value. RESULTS: Patients at
baseline had same mean age 54 years, 44 vs. 52% female, base-
line HbA1C 9.3 vs. 8.9%, access to endocrinologist 36 vs. 46%,
average number of oral antidiabetic agents 2.3 vs. 2.0, patients
with medical insurance claims for hypoglycemia 3.2 vs. 4.3%,
Charlson comorbidity score for overall comorbidities 0.64 vs.
0.82, and 6-month total health care costs $8,797 vs. $12,924 in
glargine vs. NPH initiator groups, respectively. Adjusted 1-year
mean HbA1C was 8.05 vs. 8.51% (d = -0.45, p = 0.0036) and
2-year mean HbA1C was 8.03 vs. 8.37% (d = -0.33, p = 0.0099)
for glargine and NPH, respectively. At end of 2 years, 16.6%
NPH initiators dispensed glargine prescriptions while 2.7%
glargine initiators dispensed NPH prescriptions. Adjusted rate
of patients per quarter in the ﬁrst year with medical claims
for hypoglycemia was 1.7 vs. 2.9% (d = -1.2%, p = 0.0559)
and 2-year quarterly rate was 1.55 vs. 2.51% (d = -0.96%,
p = 0.0139). Adjusted 1-year total health care costs were
$16,184 vs. $21,104 (quarterly d = -$1,034, p = 0.0372) and
2-year costs was $30,032 vs. $42,208 (quarterly d = -$1,522,
p = 0.0029). CONCLUSION: Initiation of insulin glargine, rela-
tive to NPH, was associated with sustained improvements in
glycemic control with lower rate of medically claimed hypogly-
cemia and lower total health care expenditures in patients with
T2DM.
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OBJECTIVES: To compare 1-year health care utilization and
costs in patients initiating insulin glargine vs NPH. METHODS:
Patients with T2DM (03/2001..C03/2005) who failed oral agents
and initiated insulin glargine or NPH were evaluated using
the Integrated Health Care Information System, a US managed
care health plan database. Patients were continuously enrolled
with managed care health plans for °Ý6 months before and
12 months after insulin initiation. Propensity score matched
NPH to glargine initiators by baseline demographics, HbA1c,
co-morbidities, health care utilization, and pharmacy copay-
ment. Conditional logistic regression, McNemar’s test, and
paired t-test were used to compare subsequent utilizations/ costs
between two insulin groups. Costs were paid by health insurance,
adjusting for inﬂation to the most current year value in database.
RESULTS: Matched sample (n = 1,468) was 46% female, mean
age 54.6 yrs., A1C 9.2%, Charlson Comorbidity Index (CCI)
0.69, metformin-use 77.6%, sulfonylureas 77.6%, and thiazo-
lidinedione 56%. Before matching, glargine initiators were more
likely than NPH initiators to be female, had higher HbA1c, CCI,
more use of TZD, sulfonylurea and statins, fewer visits to an
endocrinologist, higher out-of-pocket drug copayment, lower
total health care utilization and associated costs (except diabetes
medications). After propensity score matching, no differences
remained between matched pairs. During 12-month follow-up,
glargine initiators showed a lower hospitalization rate (OR:0.73,
95%CI [0.57–0.94], P = 0.0124) while outpatient and emer-
gency service utilization was not statistically different between
groups. Number needed to treat with glargine was 17 (95% CI:
9–59) to avoid hospitalization for a patient. For the same
follow-up period, glargine use on average cost $532 vs. $293 for
NPH (P < 0.0001) and $2097 vs $1820 for all antidiabetic
medications (P < 0.0001). CONCLUSION: Initiation of insulin
glargine is associated with lower rate of hospitalization com-
pared to NPH in individuals with T2DM. This clinical beneﬁt is
achieved with a modest increase in pharmacy expenditures for
treating diabetes.
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OBJECTIVES: Despite extensive use of basal-bolus and pre-
mixed analog insulin therapy, real-world comparative effective-
ness of the regimens has not been determined. METHODS:
Patients with Type 2 diabetes at two US endocrinology practice
centers were randomized to insulin glargine plus glulisine
(GLAR/GLU, n = 106) or analog premix (n = 91). Subsequent to
randomization, patients continued treatment following center’s
usual practice with no additional therapeutic protocols. Data
collected at 0, 3, 6 and 9 months included A1C, hypoglycemia,
insulin dose, concomitant medications, and therapy change.
Medication costs were estimated using published average whole-
sale price. RESULTS: Treatment groups were comparable at
baseline with mean age 56 years, 46% male, 59% Caucasian,
and 38% African-American, duration of diabetes 13 years,
HbA1C 9.25%, and BMI 35.8 kg/m2. About 70% patients used
oral hypoglycemic agent(s) during 4 months before randomiza-
tion, 88% used insulin with mean daily dose of 71IU, and 29%
had chart records for hypoglycemia. Mean follow-up time was
183 days. 1 patient (1%) randomized to GLAR/GLU switched
to premix therapy relative to 9 (10%) randomized to premix
switched to GLAR/GLU. In ITT analysis, adjusted mean
follow-up HbA1C was 6.98% in GLAR/GLU vs. 7.57% in
premix (d = -0.59%, p = 0.009) and HbA1C reduction was
2.27% (95% CI: 1.63–2.91) vs. 1.68% (1.20–2.16). Mean
number of concomitant oral anti-diabetic agents were 0.94 vs.
1.22 (d = -0.28, p = 0.041). Mean daily insulin dose was 74IU
vs. 85IU (d = -11, p = 0.267). Hypoglycemia was recorded in
charts for 36% vs. 43% (d = -7%, p = 0.374) patients in GLAR/
GLU vs. premix. Daily costs for all anti-diabetic medications
were $9.8 in GLAR/GLU vs. $11.9 in premix (d = -$2.1,
p = 0.036). Treatment costs per 1% HbA1C reduction during
follow-up period (183 days) were $790 for GLAR/GLU vs.
$1,296 for premix. CONCLUSION: In real world practices,
glargine plus glulisine, relative to analogue premix, produces
improved glycemic control with lower total diabetes medication
costs.
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OBJECTIVES: Diabetes, hypertension and high cholesterol are
all prevalent in the United States. The purpose of this research is
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